Fortress Biotech Inc. buy melinda
Startpreis
30.08.18
/
50%
1,81 €
Kursziel
17.12.18
3,61 €
Rendite (%)
-48,76 %
Endpreis
17.12.18
0,93 €
Zusammenfassung
Diese Einschätzung wurde am 17.12.18 mit einem Endkurs von 0,93 € beendet. Die BUY Einschätzung von melinda schloss mit einer Rendite von -48,76 %. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Fortress Biotech Inc. | - | - | - | - |
iShares Core DAX® | 1,05 % | -1,83 % | 12,82 % | 15,39 % |
iShares Nasdaq 100 | -0,55 % | -3,74 % | 40,63 % | 42,40 % |
iShares Nikkei 225® | -1,78 % | -8,12 % | 16,09 % | 0,89 % |
iShares S&P 500 | 0,00 % | -2,23 % | 28,39 % | 41,09 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Fortress Biotech Inc. diskutieren
SecteurProduits pharmaceutiques Agenda 08/11 Publication de résultats
Develops novel immunotherapy biologic agents
Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products.
It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National.
The National segment consists of National Holdings Corporation, an independent brokerage company.
The company was founded on June 28, 2006 in and is headquartered in New York, NY.
Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products.
It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National.
The National segment consists of National Holdings Corporation, an independent brokerage company.
The company was founded on June 28, 2006 in and is headquartered in New York, NY.
Nombre d'employés : 68 personnes.
(Vom Mitglied beendet)